Tobacco Product Standard for Nicotine Level : Protecting Against Unintended Consequences by Expanding the Scope of the Rule to All Inhaled Recreational Nicotine Products Docket No . FDA-2017-N-6189

This comment details how the proposed product standard can create unintended public health harm if the standard is written in a way that can be used by the tobacco industry to simply shift the mix of dangerous products that it markets to continue to build its markets. Specifically, if the nicotine product standard for cigarettes or even all combustible tobacco products is not implemented in the broader context of the entire recreational nicotine market, the product standard could create substantial public health risks. FDA must develop the standard in a way that explicitly considers that: 1) e-cigarettes and other non-combusted nicotine products do carry health risks, and 2) FDA resources must be devoted to targeted public education campaigns and concurrent regulatory action to ensure that the combustible product standard does not inadvertently increase nicotine use among youth and young adults.

[1]  Glen Szczypka,et al.  Vaping versus JUULing: how the extraordinary growth and marketing of JUUL transformed the US retail e-cigarette market , 2018, Tobacco Control.

[2]  F. Deleyiannis,et al.  The effects of electronic cigarette vapour on the lung: direct comparison to tobacco smoke , 2018, European Respiratory Journal.

[3]  P. Slovic,et al.  Reassessing the importance of ‘lost pleasure’ associated with smoking cessation: implications for social welfare and policy , 2017, Tobacco Control.

[4]  S. Glantz,et al.  Tobacco Industry Research on Nicotine Replacement Therapy: “If Anyone Is Going to Take Away Our Business It Should Be Us” , 2017, American journal of public health.

[5]  Kevin Conway,et al.  Developmental toxicity of nicotine: A transdisciplinary synthesis and implications for emerging tobacco products , 2017, Neuroscience & Biobehavioral Reviews.

[6]  S. Glantz,et al.  Philip Morris research on precursors to the modern e-cigarette since 1990 , 2016, Tobacco Control.

[7]  S. Glantz,et al.  Assessing tobacco regulation: moving beyond economists , 2015, Tobacco Control.

[8]  Fritz L. Laux,et al.  An evaluation of the FDA's analysis of the costs and benefits of the graphic warning label regulation , 2014, Tobacco Control.

[9]  S. Glantz,et al.  When health policy and empirical evidence collide: the case of cigarette package warning labels and economic consumer surplus. , 2014, American journal of public health.

[10]  J. Venitz,et al.  Non-clinical safety and pharmacokinetic evaluations of propylene glycol aerosol in Sprague-Dawley rats and Beagle dogs. , 2011, Toxicology.

[11]  D. Norbäck,et al.  Experimental exposure to propylene glycol mist in aviation emergency training: acute ocular and respiratory effects , 2001, Occupational and environmental medicine.

[12]  C. Coggins,et al.  Subchronic nose-only inhalation study of propylene glycol in Sprague-Dawley rats. , 1989, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[13]  V. Vávrová,et al.  Effect of the inhalation of a surface tension-reducing substance (propylene glycol) on the ultrastructure of epithelium of the respiratory passages in rabbits. , 1978, Folia morphologica.